Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

S. W. Yee, Y. Momozawa, Y. Kamatani, R. F. Tyndale, R. M. Weinshilboum, M. J. Ratain, K. M. Giacomini, Michiaki Kubo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

Original languageEnglish
Pages (from-to)423-426
Number of pages4
JournalClinical Pharmacology and Therapeutics
DOIs
Publication statusPublished - 01-11-2016

Fingerprint

Pharmacogenetics
Phenotype
Research
Pharmaceutical Preparations
Pharmacogenomic Testing

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yee, S. W. ; Momozawa, Y. ; Kamatani, Y. ; Tyndale, R. F. ; Weinshilboum, R. M. ; Ratain, M. J. ; Giacomini, K. M. ; Kubo, Michiaki. / Genomewide Association Studies in Pharmacogenomics : Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. In: Clinical Pharmacology and Therapeutics. 2016 ; pp. 423-426.
@article{376bcf456d5041b2a8d6be97063f9365,
title = "Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration",
abstract = "Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.",
author = "Yee, {S. W.} and Y. Momozawa and Y. Kamatani and Tyndale, {R. F.} and Weinshilboum, {R. M.} and Ratain, {M. J.} and Giacomini, {K. M.} and Michiaki Kubo",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/cpt.405",
language = "English",
pages = "423--426",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

Genomewide Association Studies in Pharmacogenomics : Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. / Yee, S. W.; Momozawa, Y.; Kamatani, Y.; Tyndale, R. F.; Weinshilboum, R. M.; Ratain, M. J.; Giacomini, K. M.; Kubo, Michiaki.

In: Clinical Pharmacology and Therapeutics, 01.11.2016, p. 423-426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genomewide Association Studies in Pharmacogenomics

T2 - Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

AU - Yee, S. W.

AU - Momozawa, Y.

AU - Kamatani, Y.

AU - Tyndale, R. F.

AU - Weinshilboum, R. M.

AU - Ratain, M. J.

AU - Giacomini, K. M.

AU - Kubo, Michiaki

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

AB - Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=84990196642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990196642&partnerID=8YFLogxK

U2 - 10.1002/cpt.405

DO - 10.1002/cpt.405

M3 - Article

C2 - 27256705

AN - SCOPUS:84990196642

SP - 423

EP - 426

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -